fr   en
Clinical Studies

Tableaux synoptiques (en anglais)

Parcourir par date
Rechercher par mot clé
Date: 2010-01-11
Phase: I
Anouncement: Launch
Biotech: Summit (UK) BioMarin Pharmaceuticals
Product: SMT C1100 (small molecule utrophin upregulator)
Disease: Duchenne muscular dystrophy
Other: BioMarin Pharmaceuticals has initiated a Phase I clinical study of SMT C1100 for the treatment of Duchenne muscular dystrophy.This programme was partnered with BioMarin in a multi-million dollar deal in July 2008 (See agreements).

This clinical trial is a single centre, double blind, placebo-controlled, single dose-escalation study followed by a multiple-dose study of SMT C1100 administered orally in healthy volunteers.
The primary objective is to assess the safety, tolerability and pharmacokinetics of SMT C1100 in healthy volunteers, and enable subsequent studies in patients with DMD.